Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Acacia Pharma Group plc
DescriptionIV formulation of amisulpride, an off-patent dopamine D2 and D3 receptor antagonist
Molecular Target Dopamine D2 receptor ; Dopamine D3 receptor (DRD3)
Mechanism of ActionDopamine D2 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationEmesis
Indication DetailsTreat and prevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today